Instem Plc (LON:INS), which provides software used to log and manage clinical trials, said it extended its relationship with two existing clients to land new contracts worth US$800,000.
The new deals was were for its submit product, which complies with the US Food & Drug Administration’s SEND initiative.
SEND stands for Standard for Exchange of Non-clinical Data and is an industry-wide edict that governs the way information is relayed.
"The Instem team has led and participated in the creation of the SEND standard for over 10 years and brings over 30 years of experience in developing, delivering and supporting world-class nonclinical systems and solutions for the scientific community,” said chief executive Phil Reason.
“I am delighted to say that our submit solution continues to be the most widely licensed set of SEND tools around the world, installed in over 34 sites across 12 countries, helping our customers achieve successful submissions to the FDA."
The two customers were not named, but they were identified as “top 25 global pharmaceutical companies”.
The deals start immediately and “predominantly comprise of perpetual software licence fees”.
"We are delighted to extend our relationship with two existing customers,” said CEO Reason.
“This provides further evidence of how Instem is starting to benefit from the FDA mandate requiring pre-clinical study submissions to comply with SEND."